Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Sep 18 - Sep 23
BMI 30+ or BMI 27+ with comorbidities, weight-management documentation, step therapy when applicable
FDA-approved for HIV-associated lipodystrophy, this GHRH analog reduces visceral fat by 15-20% over 26 weeks at 2mg daily without affecting subcutaneous fat stores
.png)
The material for this study was produced by Bachem (Weil am Rhein, Germany) and prepared in sterile vials allowing for daily subcutaneous self-injection (SC) of 4 mg
During the recent updates in July and August 2025, management transparently cut the 2025 sales growth outlook from 1016% to 814%, explaining the specific reasons: slower obesity drug uptake in certain markets, competition from Eli Lillys rival drug, and persistent use of compounded (unapproved) GLP-1 products in the US
Why Weight Loss Continues Beyond 48 Weeks Several factors explain why retatrutides weight loss trajectory had not plateaued by 48 or even 68 weeks: Late dose optimization
US$ 23.47
US$ 22.92
US$ 27.83
US$ 26.54
US$ 29.20
US$ 26.10
US$ 28.83
US$ 24.47
US$ 21.19
